1. Scrip
  2. >>COVID-19

Sir Mene Pangalos Outlines AZ's Trio Of COVID-19 Targets

Testing, Developing Antibodies And Repurposing Medicines

 
• By Kevin Grogan

The diagnostics tie-up with GSK on testing is a near-term move to help the UK get back to normality, the drug major's biopharmaceuticals R&D boss tells Scrip. AstraZeneca's main focus is to develop monoclonal antibodies to tackle 'wave two' of the coronavirus.

Menelas (Mene) Pangalos

A day after unveiling a pact with GlaxoSmithKline PLC and the University of Cambridge to set up a facility for COVID-19 testing, AstraZeneca PLC's head of biopharmaceuticals R&D Sir Mene Pangalos has been talking about the firm's diagnostics and therapeutic approaches to tackling coronavirus.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip